Shares of AbbVie ABBV moved higher by 0.3% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 21.46% year over year to $2.83, which beat the estimate of $2.76.
Revenue of $12,902,000,000 up by 52.16% year over year, which beat the estimate of $12,720,000,000.
Looking Ahead
The upcoming fiscal year's EPS expected to be between $10.47 and $10.49.
How To Listen To The Conference Call
Date: Oct 30, 2020
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/32j7obdj
Price Action
52-week high: $101.28
Company's 52-week low was at $62.55
Price action over last quarter: down 15.70%
Company Description
AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013. The recent announced acquisition of Allergan will add several new drugs in aesthetics and women's health.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
